Bio-Path Holdings Inc. (NASDAQ:BPTH) does about 157.79K shares in volume on a normal day but saw 6154285 shares change hands in Friday trading. The company now has a market cap of 14.60M USD and an enterprise value of about $581.75k. Its current market price is $5.16, marking an increase of 30.30% compared to the previous close of $3.96. The 52 week high reached by this stock is $13.34 whilst the lowest price level in 52 weeks is $2.92. The script in recent trading has seen the stock touch a high of $5.54 and a low of $3.93.
Bio-Path Holdings Inc. (BPTH) has a 20-day trading average at $4.94 and the current price is -61.33% off the 52-week high compared with 76.69% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.07 and its 200-day simple moving average is $6.03. If we look at the stock’s price movements over the week, volatility stands at 14.47%, which decreases to 7.16% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.65 to suggest the stock is neutral.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 13, 2017 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $4.50 and $1.50. Rodman & Renshaw initiated its price target at $5.
The current price level is 4.66%, 1.90%, and -14.80% away from its SMA20, SMA50, and SMA200 respectively, with the BPTH price moving above the 50-day SMA on August 21. Bio-Path Holdings Inc. (BPTH) stock is up 4.24% over the week and -4.44% over the past month. Its price is -35.42% year-to-date and -57.88% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.55 above consensus estimates by $0.34. The company’s next earnings report is expected on 11/12/2020, with forecasts estimating quarterly EPS at -$0.83 and -$3.14 for whole year. BPTH’s earnings per share are forecast to grow by 3.10% this year and 22.90% over next year.
Its 12-month price target is $12.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $12.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $12.00.
Outstanding shares total 3.69M with insiders holding 1.26% of the shares and institutional holders owning 11.43% of the company’s common stock. The company has a return on equity of -56.30%. The beta has a value of 2.41. Price to book ratio is 1.19.
According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has reduced its position in Bio-Path Holdings Inc. (BPTH) to 36,520 shares, mirroring a recent drop by 0.00%. Vanguard Extended Market Index Fu dumped 0.0 shares of Bio-Path Holdings Inc. common stock bringing its total worth to about $0.19 million at the end of recent close, SEC documents show. Vanguard Extended Market Index Fu isn’t the only investment manager who changed stakes and is followed by Fidelity Extended Market Index Fu, which sold off 0.0 shares to end up with 14,635 shares worth $74199.0. Fidelity Total Market Index Fund cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.09% position in Bio-Path Holdings Inc. thanks to 3392.0 shares amounting to $17197.0.